JAAHA Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davies, D. R.
Right arrow Articles by Irwin, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, D. R.
Right arrow Articles by Irwin, P. J.
Journal of the American Animal Hospital Association 40:124-130 (2004)
© 2004 American Animal Hospital Association


Original Article

Vinblastine and Prednisolone as Adjunctive Therapy for Canine Cutaneous Mast Cell Tumors

David R. Davies, BSc, BVMS (Hons), MACVSc, Kenneth M. Wyatt, BSc, BVMS, FACVSc, John E. Jardine, BVSc, MMedVet, Diplomate ACVP, Ian D. Robertson, BVSc, PhD, MACVSc and Peter J. Irwin, BVetMed, PhD, FACVSc

From the Division of Veterinary and Biomedical Sciences (Davies, Wyatt, Robertson, Irwin), Murdoch University, South Street, Murdoch 6150, Western Australia, Australia; and Vetpath Laboratory Services (Jardine), P.O. Box 18, Belmont 6984, Western Australia, Australia.

Twenty-seven dogs with inadequately excised, cutaneous mast cell tumors (MCT; 20 residual microscopic disease, seven marginal excision) were treated with a vinblastine and prednisolone chemotherapeutic protocol. Twenty dogs were available for follow-up examination after 12 months. One dog suffered local recurrence of the tumor, four dogs developed new cutaneous tumors, and one dog had both events. Fourteen dogs were free of MCT. There was no confirmed tumor-related mortality. Although toxicity from the chemotherapy was generally mild, one dog died of sepsis during treatment.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. A. London, P. B. Malpas, S. L. Wood-Follis, J. F. Boucher, A. W. Rusk, M. P. Rosenberg, C. J. Henry, K. L. Mitchener, M. K. Klein, J. G. Hintermeister, et al.
Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision
Clin. Cancer Res., June 1, 2009; 15(11): 3856 - 3865.
[Abstract] [Full Text] [PDF]


Home page
Journal of the American Animal Hospital AssociationHome page
K. Hosoya, W. C. Kisseberth, F. J. Alvarez, A. Lara-Garcia, G. Beamer, P. C. Stromberg, and C. G. Couto
Adjuvant CCNU (Lomustine) and Prednisone Chemotherapy for Dogs With Incompletely Excised Grade 2 Mast Cell Tumors
J. Am. Anim. Hosp. Assoc., January 1, 2009; 45(1): 14 - 18.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Animal Hospital Association.